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Abstract
Background: The widespread use of antiretroviral therapies has led to considerable concerns about the prevalence of
drug-resistant, as transmission of drug-resistant (TDR) strains poses a challenge for the control of the HIV-1 epidemic.
Methods: We conducted an epidemiological study enrolling treatment-naïve HIV-1-positive subjects at the Peking
Union Medical College Hospital since 1991. Drug resistance was determined by submitting the sequences to the
Stanford University Network HIV-1 database.
Results: Of 521 participants, 478 samples were amplified and sequenced successfully. HIV Transmitted drug resistance
prevalence in China was determined to be 6.7 %. We did not find significant differences in the TDR rate by
demographic characteristics. No significant time trend in the prevalence of overall TDR was observed (p > 0.05).
Conclusions: We identified an intermediate prevalence of transmitted drug resistance (TDR), exhibiting a stable time
trend. These findings enhance our understanding of HIV-1 drug resistance prevalence and time trend, and provide
some guidelines for the comprehensive public health strategy of TDR prevention.
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Background
The “Four Frees and One Care” policy implemented in
China in 2003, which provided free antiretroviral (ARV)
drugs, has been credited for significantly reducing the rate
of morbidity and mortality attributed to HIV infection in
the country [1, 2]. By August 31st 2013, HIV-1 patients liv-
ing in 31 provinces and 2215 counties had received anti-
retroviral therapy (ART) and greatly benefited from this
program. The accumulative total of treatment-experienced
patients was 234,655, with 188,126 being treated in China.
Characterized by a high replication rate [3] and the
error-prone reverse transcriptase [4, 5], HIV-1 is
extensively genetically diverse. Like those in developed
countries, the emergence and transmission of drug-
resistant HIV-1 strains is of considerable concern with the
widespread use of ART in developing countries. It has been
reported that many treated patients developed resistance
to a specific drug within a class or an entire class of ART
drugs [6], which may lead to treatment failure and limita-
tion of alteration of treatment regimen. Furthermore,
transmitted drug resistance (TDR), which is the transmis-
sion of drug-resistant variants to individuals who have
never undergone ART can occur. TDR can compromise
the efficacy of combination ARV regimens in the manage-
ment of HIV disease, becoming a major obstacle to ART.
The prevalence of TDR varies worldwide ranging from
3.2 % to 24.1 % [2, 7–22]. In China, free therapy was pro-
vided to AIDS patients in 2004, which means that there
might be transmission of drug-resistant variants. Some re-
ports have demonstrated the increasing TDR rate [22, 23].
So in this study we focused on the compare of the preva-
lent ratio of drug-resistant variants before and after 2004
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Plasma specimens were collected from HIV-1 treatment-
naïve patients enrolled in the Peking Union Medical
College Hospital. Participants had received no antiretro-
viral drugs at the time of sampling. The patients recruited
in this study were AIDS stage for their CD4 cells being
below 350 counts per microlitre and viral load exceeding
103 log. Plasma samples were shipped on dry ice and
stored at -80 °C until analysis. All patients provided a writ-
ten informed consent and their basic personal and clinical
information was acquired by face to face interview. A total
of 521 patients were enrolled, and this study was approved
by the Ethics Committee at the Institutional Review Board
of the Academy of Military Medical Sciences.
Genotypic resistance testing
Nested PCR was employed to amplify the 2161 bp
HIV-1 gag-pol gene which comprised the entire PR
gene (codons 1–99) and RT gene (codons 1–560).
HIV-1 RNA was extracted from 500 μl plasma using
the QIAamp® Viral RNA Mini Kit (Qiagen) and used
as a template for a one-step reverse transcriptase
polymerase chain reaction (RT-PCR). The RT-PCR primers
were [MAW26: 5’-TTGGAAATGTGGAAAGGAAGGAC-
3’; Vif: 5’-TGACTTTGGGGATTGTAGGGAATA-3’]. The
one-step RT-PCR reaction mixture (One Step RNA PCR
Kit (AMV), Takara) contained 5 mM MgCl2, 1 mM dNTP,
10X One Step RNA PCR Buffer (5 μl), 40 U RNase Inhibi-
tor, 5 U AMV RTase XL, 5 U AMV-optimized Taq, 20 μM
(each) primer and 2 μl of viral RNA, for a final volume of
50 μl. Two microliters of the RT-PCR mixture was used
for nested PCR, with 1.25 U Premix Ex Taq (Premix Ex
TaqTM Version 2.0, Takara) and 20 μM (each) primer
[PRO-1: 5’-CAGAGCCAACAGCCCCACCA-3’; RTO-2:
5’-TAAAATCACTAGCCATTGCTCTCC-3’, respectively]
combined to a total volume of 50 μl. Both one-step RT-
PCR and nested PCR amplifications were carried out in a
Biometra Thermocycler (Biometra). The patient-derived
PR-RT PCR products were directly sequenced with pyrose-
quencing method by the Huada Genomics Company
(China). The sequences were edited using the ContigEx-
press software and aligned using the BioEdit program. For
each patient, genotypic resistance was determined by sub-
mitting the sequences to the Stanford University Network
HIV-1 database [24].
Subtype identification
Subtype was determined by phylogenetic tree analysis of
the PR-RT fragments. Alignments also included the ref-
erence sequences representing HIV-1 genetic circulating
recombinant forms obtained from the HIV Database
[25]. The phylogenetic tree was constructed using the
Neighbor-Joining method by MEGA (Molecular Evolu-
tionary Genetic Analysis Software, Version 5.4) and gen-
etic distance reliability was evaluated using the bootstrap
test (500 bootstrap replicates).
Statistical analysis
Fisher test analysis was performed using SAS version 9.2.
All analyses were performed using a two-tailed test and p
values less than 0.05 were defined as statistically significant.
Results
Patient characteristics
The Peking Union Medical College Hospital provided sub-
jects from a widespread referral network within each of 8
provinces and metropolitan cities across China (Beijing,
Shanghai, Guangzhou, Shenzhen, Fuzhou, Henan, Yunnan,
and Xi’an) who were treatment-naïve at the time of sam-
pling. A total of 521 subjects infected with HIV-1 during
the period 1991–2009 were evaluated; and 491 (94.2 %) of
the subjects were from 2005 to 2009. The 28 samples in
year 1999–2004 are mainly from Henan (17/28, 60.7 %).
Table 1 summarizes demographic and clinical characteris-
tics of the study population. The average age was 35.49 ±
10.01 (18–65 years) and males dominated the study popu-
lation (69.3 %). More than half (77.9 %) of patients were
infected by sexual contact, of which 214 (41.1 %) was
through heterosexual contact and 182 (34.9 %) through
sex between men. The mean HIV viral RNA load was 4.54
log copies/ml.
Genetic subtypes
Based on RT-PCR and sequencing results, 478 (478/521)
samples were amplified and sequenced successfully
(GenBank accession numbers KU050197 - KU050674).
A neighbor-joining tree of isolates in our program was
constructed to determine subtype of each isolate and
sequence relatedness. Subtyping assessment results re-
vealed that substantial proportions of the study samples
were CRF01_AE (40.0 %, 191/478) and subtype B
(23.2 %, 111/478). Other subtypes included CRF07_BC
(14.2 %, 68/478), CRF08_BC (8.4 %, 40/478) and sub-
type C (1.3 %, 6/478). Two (0.42 %, 2/478) CRF02_AG
and one (0.21 %, 1/478) CRF06_CPX were also found.
Figure 1 shows the distribution of the subtypes. Of
these patients who were infected by sexual contact,
most were CRF01_AE (44.2 %, 165/373), subtype B
(16.4 %, 61/373) and CRF_07BC (16.1 %, 60/373);
whereas the most common subtype among patients
exposed to HIV-infected blood was subtype B (74.4 %,
32/43; Table 2).
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Resistance analysis
All of the fragment sequences were translated and com-
pared with the consensus B sequence in the Stanford
University Network HIV-1 database [25]. A total of 32
(6.7 %) of 478 cases were found to harbor HIV-1 strains
with at least one major drug-resistant mutation con-
ferred by nucleoside reverse transcriptase inhibitors
(NRTIs), nonnucleoside reverse transcriptase inhibitors
(NNRTIs), or protease inhibitors (PIs), of whom 28
patients had mutations associated with reduced suscepti-
bility to one ARV drug (Fig. 2). There was no significant
difference (p > 0.05) in the prevalence of drug-resistant
mutations among NRTIs (12/32), NNRTIs (11/32) and
PIs (13/32). In addition, a substantial proportion of cases
(9/11, 81.8 %) were highly resistant to NNRTIs, while
only one case (1/12, 8.3 %), and 3 cases (3/13, 23.1 %)
were highly resistant to NRTIs and PIs respectively, with
a significant difference (p = 0.0050). The most commonly
observed NNRTI resistance associated mutations were
K103N (15.6 %, 5/32) and Y181C (12.5 %, 4/32). Of 13
cases resistant to PIs, 12 cases were resistant to Nelfina-
vir (NFV) resistance.
Comparison of the resistant rate in two major risk
groups revealed that there was no significant difference
(p > 0.05) between sexually infected individuals (28/373,
7.5 %) and patients infected by blood transfusions (3/43,
7.0 %). In addition, we did not find a significant differ-
ence in resistance in patients infected through hetero-
sexual contact versus homosexual contact (p > 0.05). The
prevalence of resistance in male and female was 8.1 %
and 2.7 %, respectively (p > 0.05). Shenzhen had the
highest rate of drug resistance at 11.6 %, and there was
no significant difference (p > 0.05) among these regions
(Table 3). There were different prevalence of resistance
among subtype B, CRF_01AE and CRF_07BC/08BC (p =
0.0037). The susceptibility of CRF01_AE was signifi-
cantly higher than subtype B (p = 0.0030).
As a result of the introduction of free ART in 2004,
we compared the resistance between the two periods.
No significant difference (p > 0.05) on resistance was ob-
served in the 1991–2004 (2/28, 7.1 %) period and 2005–
2009 (30/450, 6.7 %) period. And there is also no differ-
ence in TDR prevalence between the two periods in each
origins (p > 0.05). Additionally, the differences on resist-
ance to NRTIs, NNRTIs and PIs between the two pe-
riods were not statistically significant (p > 0.05, Fig. 3).
Discussion
We report here the drug susceptibility of 521 treatment-
naïve HIV-1-infected individuals at the Peking Union
Medical College Hospital from 1991 to 2009. Four hun-
dred and seventy eight gag-pol gene sequences (478/
521) were sequenced successfully and the results of sub-
type and genetic resistance were obtained.
Various HIV-1 strains have been identified in China,
of which CRF07_BC, CRF01_AE, CRF08_BC, and B/
B’are the most common. Other reported strains include
subtype G, subtype C, CRF55_01B and numerous unique
recombinant forms (URFs) [26, 27]. Various HIV-1 sub-
types/CRFs have been disseminated among different
high risk populations. Our findings found that the most
common subtype was CRF01_AE among the patients
who were infected by sexual contact, and subtype B was

















Route of transmission, no.(%)
Heterosexual contact 214(41.1)




Year of plasma collection
1991-2004 30(5.8)
2005-2009 491(94.2)
HIV-RNA load mean(SD), log copies/ml 4.54(0.75)
Fig. 1 Distribution of HIV-1 subtypes and recombinants. The area of
every section indicates the proportion of the subtypes and
recombinants. UK: unknown
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found to circulate mainly in the blood-borne transmission
population, which were consistent with previous Chinese
studies [28, 29]. In the present study, we found that the
main route of transmission remained blood-born route for
the subjects in Henan province, of which subtype B was
dominant, as a result of HIV infection outbreak in the
mid-1990s in paid blood donors in Henan.
Our studies determined that the TDR prevalence in
China was 6.7 %, a level classified as “intermediate”
according to the WHO thresholds, and which was slightly
lower than that observed in some industrialized countries.
In the present study, we found no significant differences
in the presence of TDR by demographic characteristic,
which was similar with a previous study [8]. Here we
showed that there was no significant difference in the
prevalence of drug-resistant mutations among the three
antiretroviral classes (PI, 2.7 %; NRTI, 2.5 %; and
NNRTI, 2.3 %). In addition, we noted that the preva-
lence of HIV-1 strains with high level of resistance mu-
tations to NNRTIs were significantly higher than those
to NRTIs and PIs (p < 0.0050). The higher prevalence
may be related to mutations associated with decreased
susceptibility to NNRTIs with a low genetic barrier,
which are rapidly generated and emerge early in the
selection process [30].
It is known that there is an approximate 8–10 % gen-
etic diversity exists in pol gene among various subtypes;
therefore drug resistance susceptibility of genotype virus
may be different. Here we showed a strong association
between the prevalence of TDR and subtypes. There was
different prevalence of resistance among subtype B,
CRF_01AE and CRF_07BC/08BC. Resistance was signifi-
cantly higher in ARV-naïve patients who were infected
with subtype B than in those infected with CRF01_AE
viruses (p = 0.0030), which was similar with previously
published studies [17–19, 31, 32]. Although subtypes
may vary in mutational pathways, it is unclear whether
subtype B was more prone to mutation [33]. As the pre-
dominant prevalence in China, HIV-1 subtype B viruses
have been exposed to ARV drugs for a longer period
than other subtypes [26, 34].
This study was performed on ART-naïve individuals. It
has been reported that resistance testing prior to the ini-
tiation of treatment in untreated populations with HIV
infection is cost-effective and may be beneficial to the
patient [35, 36]. It is commonly considered that resistant
HIV-1 variants in ART-naïve patients are transmitted
from ART-experienced patients or other ART-naïve indi-
viduals with drug-resistant strains. There are some stud-
ies indicating that drug resistant mutations among
treatment-naïve patients were associated with ART used
prior to and early in the HAART era [16]. As the ART
use has been extended in China in recent years, it be-
comes increasingly important to monitor HIV-1 genetic
diversity and TDR. Hence, we also tested whether the
free ART program, which was implemented in 2003, has
influenced the prevalence of overall TDR among ART-
naïve patients in China. It should be noted that contrary
Table 2 Prevalence of subtype among HIV_1+ patients infected by different route of transmissions
Route of transmission B C CRF_01AE CRF_07BC CRF_08BC Other Total
Sexual contact 61(16.4) 3(0.1) 165(44.2) 60(16.1) 36 (9.7) 48(12.9) 373
Blood 32(74.4) 0(0.0) 2(4.7) 1(2.3) 2(4.7) 6(14.0) 43
Other 18(29.0) 3(4.8) 24(38.7) 7(29.2) 2(3.2) 8(12.9) 62
Total 111(23.2) 6(1.3) 191(10.0) 68(14.2) 40(8.4) 62(13.0) 478
Fig. 2 Resistance to different antiviral drugs in HIV-1-infected, antiretroviral therapy-naïve patients. The columns represent the various drugs and
the column height indicates the number of the cases
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to the reports from other countries that have imple-
mented broad-access programs to ART [37, 38], results
of our analysis showed that there was no time-
dependent trend in the overall TDR, origins, or in any
class of drug resistance. Although we did not observe
evidence of an increasing prevalence of TDR over years
in the sampling patients, the number of HIV-1-infected
individuals in our study may be small.
While we did not study a random sample of HIV-1-
infected individuals, this was a large, diverse population
with a wide time span from a widespread referral net-
work in China, and our study well reflects the time trend
and demographic characteristics of TDR.
Conclusions
In summary, in this study, we fulfilled the comprehen-
sive investigation on the circulation of TDR of three
ARV classes in China. The overall prevalence of TDR
remains intermediate in ART-naïve individuals, and has
a stable TDR time trend. These findings enhance our
understanding of HIV-1 drug resistance prevalence and
time trend, and provide some guidelines for proposing
efficacious and effective programs to prevent transmis-
sion of HIV-1drug resistant strains.
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Year of plasma collection
1991-2004 28 2(7.1)
2005-2009 450 30(6.7)
Fig. 3 The time-dependent trend in any class of TDR. The orange
columns represent the TDR in 1991-2004, and the blue columns
represent that in 2005-2009. The column height indicates the
number of the cases
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